These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 14571187)
1. Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial. Vuola JM; Ristola MA; Cole B; Järviluoma A; Tvaroha S; Rönkkö T; Rautio O; Arbeit RD; von Reyn CF AIDS; 2003 Nov; 17(16):2351-5. PubMed ID: 14571187 [TBL] [Abstract][Full Text] [Related]
2. Baseline mycobacterial immune responses in HIV-infected adults primed with bacille Calmette-Guérin during childhood and entering a tuberculosis booster vaccine trial. Matee M; Lahey T; Vuola JM; Mtei L; Cole BF; Bakari M; Arbeit RD; Horsburgh CR; Pallangyo K; von Reyn CF J Infect Dis; 2007 Jan; 195(1):118-23. PubMed ID: 17152015 [TBL] [Abstract][Full Text] [Related]
3. Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. von Reyn CF; Mtei L; Arbeit RD; Waddell R; Cole B; Mackenzie T; Matee M; Bakari M; Tvaroha S; Adams LV; Horsburgh CR; Pallangyo K; AIDS; 2010 Mar; 24(5):675-85. PubMed ID: 20118767 [TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis. Waddell RD; Chintu C; Lein AD; Zumla A; Karagas MR; Baboo KS; Habbema JD; Tosteson AN; Morin P; Tvaroha S; Arbeit RD; Mwinga A; von Reyn CF Clin Infect Dis; 2000 Jun; 30 Suppl 3():S309-15. PubMed ID: 10875806 [TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901. von Reyn CF; Lahey T; Arbeit RD; Landry B; Kailani L; Adams LV; Haynes BC; Mackenzie T; Wieland-Alter W; Connor RI; Tvaroha S; Hokey DA; Ginsberg AM; Waddell R PLoS One; 2017; 12(5):e0175215. PubMed ID: 28498853 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania. Lahey T; Arbeit RD; Bakari M; Horsburgh CR; Matee M; Waddell R; Mtei L; Vuola JM; Pallangyo K; von Reyn CF Vaccine; 2010 Nov; 28(48):7652-8. PubMed ID: 20875492 [TBL] [Abstract][Full Text] [Related]
7. Lymphocyte proliferation to mycobacterial antigens is detectable across a spectrum of HIV-associated tuberculosis. Lahey T; Matee M; Mtei L; Bakari M; Pallangyo K; von Reyn CF BMC Infect Dis; 2009 Feb; 9():21. PubMed ID: 19236695 [TBL] [Abstract][Full Text] [Related]
8. Interferon γ responses to mycobacterial antigens protect against subsequent HIV-associated tuberculosis. Lahey T; Sheth S; Matee M; Arbeit R; Horsburgh CR; Mtei L; Mackenzie T; Bakari M; Vuola JM; Pallangyo K; von Reyn CF J Infect Dis; 2010 Oct; 202(8):1265-72. PubMed ID: 20812851 [TBL] [Abstract][Full Text] [Related]
9. The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3). Churchyard GJ; Snowden MA; Hokey D; Dheenadhayalan V; McClain JB; Douoguih M; Pau MG; Sadoff J; Landry B Vaccine; 2015 Apr; 33(15):1890-6. PubMed ID: 25698492 [TBL] [Abstract][Full Text] [Related]
10. Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial. Nemes E; Hesseling AC; Tameris M; Mauff K; Downing K; Mulenga H; Rose P; van der Zalm M; Mbaba S; Van As D; Hanekom WA; Walzl G; Scriba TJ; McShane H; Hatherill M; Clin Infect Dis; 2018 Feb; 66(4):554-563. PubMed ID: 29028973 [TBL] [Abstract][Full Text] [Related]
11. Preventive effects of Mycobacterium vaccae on HIV-associated tuberculosis: a systematic review. Chen Q; Yang X; Li Y; He X; Ma X; Ma L; Guo Z; Li L J Evid Based Med; 2011 May; 4(2):122-9. PubMed ID: 23672702 [TBL] [Abstract][Full Text] [Related]
12. CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: A randomized, placebo-controlled trial. Masonou T; Hokey DA; Lahey T; Halliday A; Berrocal-Almanza LC; Wieland-Alter WF; Arbeit RD; Lalvani A; von Reyn CF PLoS One; 2019; 14(5):e0217091. PubMed ID: 31120957 [TBL] [Abstract][Full Text] [Related]
13. Effects of the fusion design and immunization route on the immunogenicity of Ag85A-Mtb32 in adenoviral vectored tuberculosis vaccine. Zhang Y; Feng L; Li L; Wang D; Li C; Sun C; Li P; Zheng X; Liu Y; Yang W; Niu X; Zhong N; Chen L Hum Vaccin Immunother; 2015; 11(7):1803-13. PubMed ID: 26076321 [TBL] [Abstract][Full Text] [Related]
14. The combination of plasmid interleukin-12 with a single DNA vaccine is more effective than Mycobacterium bovis (bacille Calmette-Guèrin) in protecting against systemic Mycobacterim avium infection. Martin E; Kamath AT; Briscoe H; Britton WJ Immunology; 2003 Jun; 109(2):308-14. PubMed ID: 12757627 [TBL] [Abstract][Full Text] [Related]
15. Mycobacterium vaccae vaccine to prevent tuberculosis in high risk people: a meta-analysis. Yang XY; Chen QF; Cui XH; Yu Y; Li YP J Infect; 2010 May; 60(5):320-30. PubMed ID: 20156481 [TBL] [Abstract][Full Text] [Related]